Citations

Clear

1820 citation(s) found for "Israel, E".

Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies
Levine, Todd, Bellaire, Bailey, Wang, Ningshan , Stohl, Jade, Aldridge, Georgina M. , Barboi, Alexandru , Evidente, Virgilio Gerald H. , Geschwind, Michael D. , Gil, Ramon, Gudesblatt, Mark , Khemani, Pravin , Liu, Andy , McFarland, Nikolaus R. , Miglis, Mitchell G. , Reynolds, Adam , Sahagian, Gregory , Saint-Hillaire, Marie-Helene, Schwartzbard, Julie, Yerstein, Oleg , Kaufmann, Horacio , Miglis, Mitchell G , McFarland, Nikolaus R , Gibbons, Christopher H. , Adler, Charles H. , Galasko, Douglas , González-Duarte, Alejandra , Isaacson, Stuart , Kumar, Rajeev , Lamotte, Guillaume , Reynolds, Adam, Singer, Wolfgang , Soileau, Michael J , Vernino, Steven , Freeman, Roy L. , Liu, Andy

Mayo Clinic

JAMA | March 20, 2024 | Volume: 331 | Issue: 15 | Pages: 1298

10.1001/jama.2024.0792 | PMID 38506839 Get It

ImportanceFinding a reliable diagnostic biomarker for the disorders collectively known as synucleinopathies (Parkinson disease [PD], dementia with Lewy bodies [DLB], multiple system atrophy [MSA], and pure autonomic failure [PAF]) is an urgent unmet need. Immunohistochemical detection of cutaneous phosphorylated α-synuclein may be a sensitive and specific clinical test for the diagnosis of synucleinopathies.ObjectiveTo evaluate the positivity rate of cutaneous α-synuclein deposition in patients with PD, DLB, MSA, and PAF.Design, Setting, and ParticipantsThis blinded, 30-site, cross-sectional study of academic and community-based neurology practices conducted from February 2021 through March 2023 included patients aged 40 to 99 years with a clinical diagnosis of PD, DLB, MSA, or PAF based on clinical consensus criteria and confirmed by an expert review panel and control participants aged 40 to 99 years with no history of examination findings or symptoms suggestive of a synucleinopathy or neurodegenerative disease. All participants completed detailed neurologic examinations and disease-specific questionnaires and underwent skin biopsy for detection of phosphorylated α-synuclein. An expert review panel blinded to pathologic data determined the final participant diagnosis.ExposureSkin biopsy for detection of phosphorylated α-synuclein.Main OutcomesRates of detection of cutaneous α-synuclein in patients with PD, MSA, DLB, and PAF and controls without synucleinopathy.ResultsOf 428 enrolled participants, 343 were included in the primary analysis (mean [SD] age, 69.5 [9.1] years; 175 [51.0%] male); 223 met the consensus criteria for a synucleinopathy and 120 met criteria as controls after expert panel review. The proportions of individuals with cutaneous phosphorylated α-synuclein detected by skin biopsy were 92.7% (89 of 96) with PD, 98.2% (54 of 55) with MSA, 96.0% (48 of 50) with DLB, and 100% (22 of 22) with PAF; 3.3% (4 of 120) of controls had cutaneous phosphorylated α-synuclein detected.Conclusions and RelevanceIn this cross-sectional study, a high proportion of individuals meeting clinical consensus criteria for PD, DLB, MSA, and PAF had phosphorylated α-synuclein detected by skin biopsy. Further research is needed in unselected clinical populations to externally validate the findings and fully characterize the potential role of skin biopsy detection of phosphorylated α-synuclein in clinical care.
Testing for SARS-CoV-2: lessons learned and current use cases
Theel, Elitza S. , Kirby, James E. , Pollock, Nira R.

Mayo Clinic

Clinical Microbiology Reviews | March 17, 2024 | Volume: 37 | Issue: 2 | Pages: No page available

10.1128/cmr.00072-23 | PMID 38488364 Get It

SUMMARY The emergence and worldwide dissemination of SARS-CoV-2 required both urgent development of new diagnostic tests and expansion of diagnostic testing capacity on an unprecedented scale. The rapid evolution of technologies that allowed testing to move out of traditional laboratories and into point-of-care testing centers and the home transformed the diagnostic landscape. Four years later, with the end of the formal public health emergency but continued global circulation of the virus, it is important to take a fresh look at available SARS-CoV-2 testing technologies and consider how they should be used going forward. This review considers current use case scenarios for SARS-CoV-2 antigen, nucleic acid amplification, and immunologic tests, incorporating the latest evidence for analytical/clinical performance characteristics and advantages/limitations for each test type to inform current debates about how tests should or should not be used.
Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline
Duarte‐Rojo, Andrés , Taouli, Bachir , Leung, Daniel H. , Levine, Deborah , Nayfeh, Tarek , Alsawaf, Yahya , Saadi, Samer , Majzoub, Abdul M., Haffar, Samir , Dundar, Ayca , Sterling, Richard K. , Hasan, Bashar , Alsawaf, Yahya , Majzoub, Abdul Mounaem, Murad, M Hassan , Rockey, Don C , Alsawas, Mouaz , Sterling, Richard K , Duarte-Rojo, Andres , Nayfeh, Tarek , Levine, Deborah , Taouli, Bachir , Saadi, Samer , Hasan, Bashar , Manolopoulos, Apostolos , Murad, M. Hassan , Rockey, Don C. , Alsawas, Mouaz

Mayo Clinic

Hepatology | March 15, 2024 | Volume: 81 | Issue: 2 | Pages: 725-748

10.1097/hep.0000000000000852 | PMID 38489521 Get It

Background and Aims: Transient elastography (TE), shear wave elastography, and/or magnetic resonance elastography (MRE), each providing liver stiffness measurement (LSM), are the most studied imaging-based noninvasive liver disease assessment (NILDA) techniques. To support the American Association for the Study of Liver Diseases guidelines on NILDA, we summarized the evidence on the accuracy of these LSM methods to stage liver fibrosis (F). Approach and Results: A comprehensive search for studies assessing LSM by TE, shear wave elastography, or MRE for the identification of significant fibrosis (F2-4), advanced fibrosis (F3-4), or cirrhosis (F4), using histopathology as the standard of reference by liver disease etiology in adults or children from inception to April 2022 was performed. We excluded studies with <50 patients with a single disease entity and mixed liver disease etiologies (with the exception of HCV/HIV coinfection). Out of 9447 studies, 240 with 61,193 patients were included in this systematic review. In adults, sensitivities for the identification of F2-4 ranged from 51% to 95%, for F3-4 from 70% to 100%, and for F4 from 60% to 100% across all techniques/diseases, whereas specificities ranged from 36% to 100%, 74% to 100%, and 67% to 99%, respectively. The largest body of evidence available was for TE; MRE appeared to be the most accurate method. Imaging-based NILDA outperformed blood-based NILDA in most comparisons, particularly for the identification of F3-4/F4. In the pediatric population, imaging-based NILDA is likely as accurate as in adults. Conclusions: LSM from TE, shear wave elastography, and MRE shows acceptable to outstanding accuracy for the detection of liver fibrosis across various liver disease etiologies. Accuracy increased from F2-4 to F3-4 and was the highest for F4. Further research is needed to better standardize the use of imaging-based NILDA, particularly in pediatric liver diseases.
Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline
Patel, Keyur , Asrani, Sumeet K. , Fiel, Maria Isabel , Levine, Deborah , Leung, Daniel H. , Duarte‐Rojo, Andrés , Dranoff, Jonathan A. , Nayfeh, Tarek , Hasan, Bashar , Alsawaf, Yahya , Saadi, Samer , Majzoub, Abdul M., Ding, Jingyi , Sofiyeva, Nigar , Sterling, Richard K. , Taddei, Tamar H , Alsawaf, Yahya , Saadi, Samer , Majzoub, Abdul Mounaem, Manolopoulos, Apostolos , Alzuabi, Muayad , Ding, Jingyi , Sofiyeva, Nigar , Murad, Mohammad H, Alsawas, Mouaz , Rockey, Don C , Sterling, Richard K , Asrani, Sumeet K , Duarte-Rojo, Andres , Nayfeh, Tarek , Dranoff, Jonathan A , Fiel, Maria Isabel , Levine, Deborah , Hasan, Bashar , Manolopoulos, Apostolos , Murad, M. Hassan , Alsawas, Mouaz , Rockey, Don C.

Mayo Clinic

Hepatology | March 15, 2024 | Volume: 81 | Issue: 1 | Pages: 358-379

10.1097/hep.0000000000000842 | PMID 38489517 Get It

Background and Aims: Blood-based biomarkers have been proposed as an alternative to liver biopsy for noninvasive liver disease assessment in chronic liver disease. Our aims for this systematic review were to evaluate the diagnostic utility of selected blood-based tests either alone, or in combination, for identifying significant fibrosis (F2-4), advanced fibrosis (F3-4), and cirrhosis (F4), as compared to biopsy in chronic liver disease. Approach and Results: We included a comprehensive search of databases including Ovid MEDLINE(R), EMBASE, Cochrane Database, and Scopus through to April 2022. Two independent reviewers selected 286 studies with 103,162 patients. The most frequently identified studies included the simple aspartate aminotransferase-to-platelet ratio index and fibrosis (FIB)-4 markers (with low-to-moderate risk of bias) in HBV and HCV, HIV-HCV/HBV coinfection, and NAFLD. Positive (LR+) and negative (LR−) likelihood ratios across direct and indirect biomarker tests for HCV and HBV for F2-4, F3-4, or F4 were 1.66–6.25 and 0.23–0.80, 1.89–5.24 and 0.12–0.64, and 1.32–7.15 and 0.15–0.86, respectively; LR+ and LR− for NAFLD F2-4, F3-4, and F4 were 2.65–3.37 and 0.37–0.39, 2.25–6.76 and 0.07–0.87, and 3.90 and 0.15, respectively. Overall, the proportional odds ratio indicated FIB-4 <1.45 was better than aspartate aminotransferase-to-platelet ratio index <0.5 for F2-4. FIB-4 >3.25 was also better than aspartate aminotransferase-to-platelet ratio index >1.5 for F3-4 and F4. There was limited data for combined tests. Conclusions: Blood-based biomarkers are associated with small-to-moderate change in pretest probability for diagnosing F2-4, F3-4, and F4 in viral hepatitis, HIV-HCV coinfection, and NAFLD, with limited comparative or combination studies for other chronic liver diseases.
Noninvasive liver disease assessment to identify portal hypertension: Systematic and narrative reviews supporting the AASLD Practice Guideline
Rockey, Don C. , Duarte‐Rojo, Andrés , Patel, Keyur , Nayfeh, Tarek , Alsawaf, Yahya , Saadi, Samer , Malandris, Konstantinos , Sterling, Richard K. , Duarte-Rojo, Andres , Hasan, Bashar , Sterling, Richard K , Nayfeh, Tarek , Rockey, Don C , Alsawaf, Yahya , Saadi, Samer , Alsawas, Mouaz , Levine, Deborah, Asrani, Sumeet K. , Hasan, Bashar , Murad, M. Hassan

Mayo Clinic

Hepatology | March 15, 2024 | Volume: 81 | Issue: 3 | Pages: 1086-1104

10.1097/hep.0000000000000841 | PMID 38489516 Get It

Background and Aims: Portal hypertension is a serious complication of cirrhosis, which leads to life-threatening complications. HVPG, a surrogate of portal pressure, is the reference standard test to assess the severity of portal hypertension. However, since HVPG is limited by its invasiveness and availability, noninvasive liver disease assessments to assess portal pressure, especially clinically significant portal hypertension (CSPH), are needed. Approach and Results: We conducted a systematic review of Ovid MEDLINE(R) Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus from each database’s inception to April 22, 2022. We included only studies in English that examined ≥50 patients in single liver disease etiologies, which compared noninvasive tests (blood and/or imaging) to HVPG for predicting clinically significant portal hypertension (CSPH; defined as HVPG ≥ 10 mm Hg) in patients with chronic liver disease. Outcomes included measures of diagnostic test accuracy. Additionally, a narrative review of studies not eligible for the systematic review is also provided. Nine studies with 2492 patients met the inclusion criteria. There was substantial heterogeneity with regard to liver disease studied and cutoff values used to detect CSPH. Blood-based tests, including aspartate-to-platelet ratio index (APRI) (56% sensitivity and 68% specificity) and FIB-4 (54% sensitivity and 73% specificity) had low accuracy measures. Imaging-based tests (transient elastography and shear wave elastography detection of liver stiffness measurement [LSM]) had better accuracy but also had substantial variation; at 15 kPa, TE sensitivity was 90%–96% and specificity was 48%–50%, while at 25 kPa, its sensitivity and specificity were 57%–85% and 82%–93%, respectively. The narrative review suggested that imaging-based tests are the best available noninvasive liver disease assessment to detect CSPH; CSPH is highly unlikely to be present at an LSM ≤15 kPa and likely to be present at an LSM ≥25 kPa. Conclusions: While imaging-based noninvasive liver disease assessment appeared to have higher accuracy than blood-based tests to detect CSPH, only 9 studies fit the a priori established inclusion criteria for the systematic review. In addition, there was substantial study heterogeneity and variation in cutoffs for LSM to detect CSPH, limiting the ability to establish definitive cutoffs to detect CSPH.
Pharmacotherapeutic Considerations in the Treatment of Nontuberculous Mycobacterial Infections: A Primer for Clinicians
Cimino, Christo , Rivera, Christina G. , Pearson, Jeffrey C , Colton, Benjamin , Slain, Douglas , Mahoney, Monica V. , Rivera, Christina G , Mahoney, Monica V

Mayo Clinic

Open Forum Infectious Diseases | March 15, 2024 | Volume: 11 | Issue: 4 | Pages: No page available

10.1093/ofid/ofae128 | PMID 38560605 Get It

Abstract Nontuberculous mycobacteria (NTM) can cause a variety of infections, including serious pulmonary disease. Treatment encompasses polypharmacy, with a targeted regimen of 2–5 active medications, depending on site of infection, species, and clinical characteristics. Medications may include oral, intravenous, and inhalational routes. Medication acquisition can be challenging for numerous reasons, including investigational status, limited distribution models, and insurance prior authorization. Additionally, monitoring and managing adverse reactions and drug interactions is a unique skill set. While NTM is primarily medically managed, clinicians may not be familiar with the intricacies of medication selection, procurement, and monitoring. This review offers insights into the pharmacotherapeutic considerations of this highly complex disease state, including regimen design, medication acquisition, safety monitoring, relevant drug–drug interactions, and adverse drug reactions.